Events
Combioxin SA announced today that first-in-human clinical results with CAL02 in severe pneumonia patients in ICU will be presented during the ESICM’s annual congress, LIVES 2018, taking place October 20-24, 2018 in Paris, France.
The survey provides latest insights into the status quo and future of drug product formulation and its potential to refine all steps in the biopharmaceutical value chain.
Smart services to be showcased include electronic sick leave attestation, online permits for imported drugs, ‘Sanad &Rahma’ & electronic birth and death certificates
Apogenix announced today that company representatives will attend several upcoming international conferences. In a total of five presentations, Apogenix will give updates on its hexavalent TNF superfamily receptor agonists (HERA-ligands) as well as its phase III-ready lead drug candidate asunercept.
Eli Lilly and Company presented positive data from two Phase III clinical trials at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Chicago yesterday.
The data was presented in a poster session on Saturday, October 20, 2018 at the 2018 American College of Rheumatology (ACR/ARHP) Annual Meeting in Chicago, IL
Johnson & Johnson’s JLABS incubator in San Francisco recently convened a meeting of biopharma industry executives. One of the hot topics for one of the panels was the competition for talent.
MagForce AG is pleased to announce that it will host a scientific lunch symposium titled “Local Therapies for Malignant Gliomas” on Tuesday, October 23, 2018 at the 18th European Congress of Neurosurgery in Brussels, Belgium.
Mesothelioma is a rare cancer that develops in the lining of the lungs, abdomen, or cardiovascular cavity. A 2017 study reported that the number of people affected by this rare cancer is between 2,400 - 2,800 individuals per year in the United States alone.
AstraZeneca and Merck & Co. presented results at the Presidential Symposium at the European Society for Medical Oncology 2018 Congress held in Munich Germany describing its Phase III SOLO-1 trial of Lynparza (olaparib) in ovarian cancer.
PRESS RELEASES